Request the White Paper: Automated Formulation and Filling to Support Scaling Tumor-Infiltrating Lymphocyte Therapy Manufacturing

Access CTMC White Paper: Automated Formulation and Filling to Support Scaling Tumor-Infiltrating Lymphocyte Therapy Manufacturing

CTMC evaluated the Xiogenix ARES™ X20+, comparing automated and manual fill-finish performance across processing efficiency, fill accuracy, cryoprotectant exposure, and cell quality. Explore the findings.
Name

First NameLast Name
Email
example@example.com
Interested in what these findings could mean for your process? Connect with the Xiogenix team to discuss your formulation and fill-finish workflow.

Inquiries can be directed to kate.pavletich@xiogenix.com.
Should be Empty:

Access CTMC White Paper: Automated Formulation and Filling to Support Scaling Tumor-Infiltrating Lymphocyte Therapy Manufacturing